Announcements Trials
Browse Landscape

Phase

Phase 2 13Phase 1 10Phase 3 7Phase 4 4Phase 2/3 2Phase 1/2 2

Status

Completed 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 5NET 4Endocrine 4Gastrointestinal 2Breast 2Tumor-Agnostic 1Thoracic 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Neuroendocrine Tumors 3Pancreatic Neuroendocrine Tumors 1Neoplasms 1Lung Neoplasms 1Carcinoma, Large Cell 1Carcinoid Tumor 1

Interventions

Octreotide 4Everolimus 4lanreotide 3pasireotide 2Carboplatin 2surufatinib 1lutetium Lu 177 dotatate 1gadoteridol 1gadoterate meglumine 1gadolinium ethoxybenzyl DTPA 1gadodiamide 1gadobutrol 1gadobenic acid 1arginyllysine 1Surveys and Questionnaires 1Sunitinib 1Somatostatin 1Positron Emission Tomography Computed Tomography 1Paclitaxel 1Neuropsychological Tests 1Magnetic Resonance Spectroscopy 1Diazoxide 1Cisplatin 1Cabergoline 164Cu-DOTATATE 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 4 × Everolimus × NET × Clear all
NCT02842749 2025-02-10

Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China

Novartis

Phase 4 Completed
61 enrolled 9 charts
EndocrineGastrointestinalNET

Pancreatic Neuroendocrine Tumors

NCT01789281 2021-06-11

Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.

Novartis

Phase 4 Completed
34 enrolled 8 charts
EndocrineNET

Carcinoid Tumor, Neoplasms, Neuroendocrine Tumors

NCT01595009 2018-11-29

An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1)

Novartis

Phase 4 Completed
246 enrolled 16 charts
EndocrineNET

Neuroendocrine Tumors

NCT01317615 2016-03-30

RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation

Novartis

Phase 4 Completed
49 enrolled 11 charts
EndocrineNETThoracic

Lung Neoplasms, Carcinoma, Large Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡